Biochemical changes of mevalonate pathway in human colorectal cancer

Research output: Contribution to journalArticle

Abstract

Background: Alterations in the mevalonate pathway may contribute to malignant cell growth. There are differences in the aetiology, clinical behaviour, pathological and genetic features in cancer of the right versus the left colon. Here, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, farnesylpyrophosphate (FPP) synthase and farnesyltransferase (Ftase) activities were measured in human colorectal cancer (CRC) and normal mucosa in order to evaluate their role as potential markers of malignancy, also in relation to cancer location. Patients and Methods: HMG-CoA reductase, FPP synthase and Ftase activities were determined in CRC and normal mucosa of 90 patients by radiochemical assay. Results: The enzymatic activities were higher in cancer than in normal mucosa. The tumours located at the left side showed higher HMG-CoA reductase activity, whereas the right side tumours showed higher levels of Ftase and FPP synthase activity. Conclusion: The determination of mevalonate pathway enzymes in relation to CRC location may be clinically relevant in designing anticancer targeted therapies.

Original languageEnglish
Pages (from-to)3393-3397
Number of pages5
JournalAnticancer Research
Volume25
Issue number5
Publication statusPublished - Sep 2005

Fingerprint

Mevalonic Acid
Colorectal Neoplasms
Farnesyltranstransferase
Neoplasms
Oxidoreductases
Mucous Membrane
Coenzyme A
Colon
Enzymes
Growth
farnesyl pyrophosphate

Keywords

  • Colorectal cancer
  • Mevalonate pathway

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Biochemical changes of mevalonate pathway in human colorectal cancer. / Caruso, Maria Gabriella; Notarnicola, Maria.

In: Anticancer Research, Vol. 25, No. 5, 09.2005, p. 3393-3397.

Research output: Contribution to journalArticle

@article{cc15ce9110ef49ef907e966f2f2b0036,
title = "Biochemical changes of mevalonate pathway in human colorectal cancer",
abstract = "Background: Alterations in the mevalonate pathway may contribute to malignant cell growth. There are differences in the aetiology, clinical behaviour, pathological and genetic features in cancer of the right versus the left colon. Here, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, farnesylpyrophosphate (FPP) synthase and farnesyltransferase (Ftase) activities were measured in human colorectal cancer (CRC) and normal mucosa in order to evaluate their role as potential markers of malignancy, also in relation to cancer location. Patients and Methods: HMG-CoA reductase, FPP synthase and Ftase activities were determined in CRC and normal mucosa of 90 patients by radiochemical assay. Results: The enzymatic activities were higher in cancer than in normal mucosa. The tumours located at the left side showed higher HMG-CoA reductase activity, whereas the right side tumours showed higher levels of Ftase and FPP synthase activity. Conclusion: The determination of mevalonate pathway enzymes in relation to CRC location may be clinically relevant in designing anticancer targeted therapies.",
keywords = "Colorectal cancer, Mevalonate pathway",
author = "Caruso, {Maria Gabriella} and Maria Notarnicola",
year = "2005",
month = "9",
language = "English",
volume = "25",
pages = "3393--3397",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Biochemical changes of mevalonate pathway in human colorectal cancer

AU - Caruso, Maria Gabriella

AU - Notarnicola, Maria

PY - 2005/9

Y1 - 2005/9

N2 - Background: Alterations in the mevalonate pathway may contribute to malignant cell growth. There are differences in the aetiology, clinical behaviour, pathological and genetic features in cancer of the right versus the left colon. Here, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, farnesylpyrophosphate (FPP) synthase and farnesyltransferase (Ftase) activities were measured in human colorectal cancer (CRC) and normal mucosa in order to evaluate their role as potential markers of malignancy, also in relation to cancer location. Patients and Methods: HMG-CoA reductase, FPP synthase and Ftase activities were determined in CRC and normal mucosa of 90 patients by radiochemical assay. Results: The enzymatic activities were higher in cancer than in normal mucosa. The tumours located at the left side showed higher HMG-CoA reductase activity, whereas the right side tumours showed higher levels of Ftase and FPP synthase activity. Conclusion: The determination of mevalonate pathway enzymes in relation to CRC location may be clinically relevant in designing anticancer targeted therapies.

AB - Background: Alterations in the mevalonate pathway may contribute to malignant cell growth. There are differences in the aetiology, clinical behaviour, pathological and genetic features in cancer of the right versus the left colon. Here, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, farnesylpyrophosphate (FPP) synthase and farnesyltransferase (Ftase) activities were measured in human colorectal cancer (CRC) and normal mucosa in order to evaluate their role as potential markers of malignancy, also in relation to cancer location. Patients and Methods: HMG-CoA reductase, FPP synthase and Ftase activities were determined in CRC and normal mucosa of 90 patients by radiochemical assay. Results: The enzymatic activities were higher in cancer than in normal mucosa. The tumours located at the left side showed higher HMG-CoA reductase activity, whereas the right side tumours showed higher levels of Ftase and FPP synthase activity. Conclusion: The determination of mevalonate pathway enzymes in relation to CRC location may be clinically relevant in designing anticancer targeted therapies.

KW - Colorectal cancer

KW - Mevalonate pathway

UR - http://www.scopus.com/inward/record.url?scp=23344432149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23344432149&partnerID=8YFLogxK

M3 - Article

C2 - 16101154

AN - SCOPUS:23344432149

VL - 25

SP - 3393

EP - 3397

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -